Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
Bisaro Paul reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC director Paul Bisaro received an equity award in the form of 59,701 restricted stock units (RSUs) of common stock at no purchase price. Each RSU represents a right to one share and will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting. After this grant, Bisaro directly holds 157,142 shares of common stock.
Kumar Rashmi reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC director Rashmi Kumar received an equity grant of 59,701 restricted stock units (RSUs) of common stock. The RSUs were granted at no cash cost and bring Kumar’s direct holdings to 186,889 shares. Each RSU represents a contingent right to receive one share of common stock and will vest on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting.
Myriad Genetics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the Amended and Restated 2012 Employee Stock Purchase Plan, increasing the shares authorized for issuance under the plan by an additional 4,000,000 shares.
They also approved the 2026 Employee, Director and Consultant Equity Incentive Plan, which provides for 6,400,000 shares of common stock plus 2,063,567 shares rolled over from the 2017 plan, for a total of 8,463,567 shares, with the reserve potentially rising to a maximum of 8,659,575 shares as prior awards lapse. Three Class III directors were elected to terms expiring at the 2029 annual meeting, Ernst & Young LLP was ratified as independent auditor for the year ending December 31, 2026, and an advisory vote approved named executive officer compensation. A quorum of 77,758,631 shares, representing approximately 82.33% of the 94,443,029 shares outstanding as of the April 8, 2026 record date, was present or represented.
Jampa Raj reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC Chief Technology Officer Raj Jampa received an equity grant of 251,889 restricted stock units. The award has no cash purchase price and represents a contingent right to receive an equal number of common shares. According to the terms, the units vest in four equal annual installments beginning on the first anniversary of the grant date, aligning the CTO’s compensation with long-term company performance.
MYRIAD GENETICS INC filed an initial ownership report for Raj Jampa, who serves as Chief Technology Officer. This Form 3 filing lists him as an officer but does not show any stock or option transactions, so it simply establishes his status as an insider for future reporting.
Myriad Genetics director Paul Bisaro reported an open-market purchase of 7,500 shares of Common Stock at $3.685 per share. After this transaction, he directly holds 97,441 shares. This filing highlights a personal increase in his equity stake in the company.
Myriad Genetics Inc. ownership filing shows State Street Corporation beneficially owned 4,424,027 shares of Common Stock, representing 4.7% of the class as of 03/31/2026. The filing reports shared voting power of 4,164,534 shares and shared dispositive power of 4,424,027.
The submission is a Schedule 13G indicating passive investment classification and lists related State Street advisory entities; signature dated 05/12/2026.
Myriad Genetics reported modest Q1 2026 revenue growth but a larger net loss. Revenue rose to $200.4 million from $195.9 million, driven by stronger Mental Health sales and higher Cancer Care Continuum volume, partially offset by lower Prenatal Health revenue.
The company posted a net loss of $34.1 million versus near breakeven a year ago, mainly due to the absence of a prior one-time tax benefit and a $5.4 million goodwill and long‑lived asset impairment. Operating loss was $30.7 million compared with $29.0 million. Cash and cash equivalents declined to $124.4 million from $149.6 million, with operating cash outflow of $15.7 million. Long‑term debt remained around $125.0 million under a SOFR‑based term loan maturing in 2030.
Myriad Genetics reported first quarter 2026 revenue of $200.4 million, up 2% year-over-year, driven by growth in Cancer Care Continuum and Mental Health testing that offset weaker Prenatal Health demand. Total test volumes were 385,000, flat year-over-year, with mix shifting toward oncology and mental health.
The company posted a GAAP net loss of $34.1 million, or $0.36 per share, while adjusted loss per share was $0.09 and adjusted EBITDA was $(4.5) million. Management reiterated full-year 2026 guidance for revenue of $860–$880 million and adjusted EBITDA of $37–$49 million, and ended the quarter with $124.4 million in cash and cash equivalents.
MYRIAD GENETICS INC Chief Commercial Officer Brian J. Donnelly had 55,975 shares of Common Stock withheld at $4.80 per share to cover tax obligations. These shares were withheld in connection with the vesting of previously granted restricted stock units, and he now directly holds 568,363 shares.